Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)

NCT04838223 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-01-27

No results posted yet for this study

Summary

This study is designed to measure how common nerve abnormalities are within a group of patients who feel discomfort within their eyes.

Conditions

  • Dry Eye
  • Neuropathic Pain

Interventions

OTHER

Hyperosmolar Response

A single drop of hypertonic sodium chloride solution at room temperature will be instilled in each eye and change in pain/other symptoms after up to 90 seconds of application (to account for any initial irritation symptoms) will be observed.

OTHER

Proparacaine Challenge Test

A single drop of Proparacaine hydrochloride ophthalmic solution, (Alcaine®, 0.5%) will be used on each eye respectively and any change in pain/other symptoms will be noted after 90 seconds (to account for initial discomfort from the preservative in Proparacaine solution).

OTHER

Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers

The CLDEQ-8 is a validated eight-item scaled questionnaire developed to reflect the overall opinion of soft contact lenses.

OTHER

Ocular Pain Assessment Survey (OPAS)

Twenty seven-item quantitative questionnaire designed to provide an assessment of the symptoms and quality of life effect of ocular pain \[18\]. The 27 items of the OPAS questionnaire are graded on a scale of 0 to 10, or 10 to 100, where 0 indicates none and 10 or 100 indicate maximum.

OTHER

Visual Analogue Questionnaire

Symptoms of ocular comfort and dryness will be graded for each eye on a scale of 0-10, where 0=extremely uncomfortable, extremely dry and 10=excellent comfort, no dryness. An average rating will be provided for the morning, afternoon and evening.

Sponsors & Collaborators

  • CooperVision International Limited (CVIL)

    collaborator INDUSTRY
  • Bausch & Lomb Incorporated

    collaborator INDUSTRY
  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • Pedram Hamrah, MD · Tufts Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-02
Primary Completion
2025-12-31
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04838223 on ClinicalTrials.gov